Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Polycystic Ovary Syndrome 1Non-alcoholic Fatty Liver Disease 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 28Radiotherapy 20pembrolizumab 9Paclitaxel 9Surveys and Questionnaires 8Cetuximab 8Fluorouracil 7Docetaxel 7Radiotherapy, Intensity-Modulated 6Carboplatin 6apatinib 5Low-Level Light Therapy 5Blood Specimen Collection 5durvalumab 4Standard of Care 4Magnetic Resonance Imaging 4Gemcitabine 4Cyclophosphamide 4Celecoxib 4Tegafur 3Radiation 3Oncolytic Virotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lidocaine 3Immunoenzyme Techniques 3Drug Therapy 3Chemotherapy, Adjuvant 3Biopsy 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Head and Neck Neoplasms × Canagliflozin × Clear all
NCT04073680 2020-05-21

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra Pharma

Phase 1/2 Unknown
60 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡